Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Read Why Imara Shares Are Falling Today

  • Imara Inc (NASDAQ:IMRAshares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. 
  • Data from the sickle cell disease study interim analysis demonstrated that tovinontrine was generally well-tolerated.
  • Four (3.6%) participants discontinued before week 24 due to adverse events.
  • The median annualized vaso-occlusive crisis (VOC) rate in the placebo group was 2.02 per year and 1.89 per year in the high dose tovinontrine group, for a treatment difference of 0.13 VOCs per year, or 6.4%. 
  • Related: Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial.
  • The median annualized rate of VOCs in the low dose tovinontrine group was zero compared to 2.02 in the placebo group.
  • Compared to the placebo, the low dose tovinontrine group experienced an increase in median time to first VOC and a higher proportion of VOC-free participants. 
  • Also, no meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.
  • No meaningful improvements were observed in most disease-related biomarkers, including total hemoglobin (Hb).
  • Imara also announced that it would discontinue the Ardent and Forte trials and the further development of tovinontrine in sickle cell disease and beta-thalassemia.
  • Price Action: IMRA shares are down 33.40% at $1.09 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.